Takeda Pharmaceuticals International, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.4M
Doctors Paid
61
Transactions
400
2019 Total
$1.4M
Payment Breakdown by Category
Research$3.1M (70.5%)
Consulting$503,642 (11.4%)
Travel$270,183 (6.1%)
Food & Beverage$5,771 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 64 | 70.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $525,352 | 56 | 11.9% |
| Consulting Fee | $503,642 | 86 | 11.4% |
| Travel and Lodging | $270,183 | 109 | 6.1% |
| Food and Beverage | $5,771 | 85 | 0.1% |
Payments by Type
Research
$3.1M
64 transactions
General
$1.3M
336 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Synergistic effect of Vedolizumab and Pentoxifylline in the management of patients with Inflammatory Bowel Disease | $292,577 | 0 | 3 |
| Optimizing therapeutic response to vedolizumab in Crohn's disease patients with assessment of intestinal barrier function | $244,969 | 0 | 2 |
| A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder | $239,575 | 0 | 2 |
| A Randomized Evaluation of Changes in Anxiety and Depression, Patient Reported Outcomes, Service Utilization and Patient Satisfaction Scores in IBD Patients Comparing Standard of Care Medical Treatment to Structured Psychosocial Care in Addition to Standa | $237,600 | 0 | 5 |
| Adjunctive Vortioxetine or Placebo for Negative Symptoms and Cognitive Impairment in Schizophrenia | $225,334 | 0 | 2 |
| Longitudinal changes of patient reported outcomes and quality of life measures in inflammatory bowel disease | $162,000 | 0 | 1 |
| Investigating the Role of a47 Integrin as a Therapeutic Target in Microscopic Colitis | $147,033 | 0 | 2 |
| INDUCTION OF RESPONSE AND REMISSION OF VEDOLIZUMAB MONOTHERAPY VS COMBINATION THERAPY WITH TACROLIMUS IN PATIENTS WITH ULCERATIVE COLITIS | $144,379 | 0 | 3 |
| Remediation of age-related cognitive decline- vortioxetine and cognitive training | $143,809 | 0 | 1 |
| Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis | $108,248 | 0 | 2 |
| Pilot study of Therapy with Ixazomib and Steroids in Highly Sensitized Patients Awaiting Kidney Transplant | $106,085 | 0 | 1 |
| Biomarkers for intestinal permeability in patients with functional lower gastrointestinal disorders associated with constipation | $105,051 | 0 | 1 |
| A randomized, double-blind, placebo controlled study of Vedolizumab for the prevention of post-operative Crohn's disease recurrence | $83,878 | 0 | 1 |
| Investigating the Role of a4B7 Integrin as a Therapeutic Target in Microscopic Colitis | $73,516 | 0 | 1 |
| Pattern Separation, BDNF, and Mechanisms of Vortioxetine | $72,466 | 0 | 1 |
| Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-Label, Flexible-Dose Vortioxetine | $71,842 | 0 | 12 |
| Vortioxetine versus Placebo in Major Depressive Disorder Comorbid with Social Anxiety Disorder | $61,804 | 0 | 1 |
| Efficacy and Safety of Vedolizumab in a nationwide cohort elderly IBD patients | $61,362 | 0 | 2 |
| Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohns disease through Serum Proteomic Biomarkers | $61,075 | 0 | 1 |
| Can Vedolizumab Drug Levels & Presence of Antibodies Help Distinguish Clinical and Biochemical Response | $60,804 | 0 | 2 |
| Development of mass cytometry as a tool for vedolizumab mode of action studies | $53,650 | 0 | 1 |
| Assessing Real-life Experience with Vedolizumab in Crohns Disease and Ulcerative Colitis | $46,549 | 0 | 1 |
| Efficacy of Influenza, Pneumococcal, and Hepatitis B vaccines in Inflammatory Bowel Disease patients treated with Vedolizumab | $45,923 | 0 | 2 |
| Clinical Outcomes with Vedolizumab use Among Inflammatory Bowel Disease Patients- A Peek into the Future | $45,513 | 0 | 2 |
| Expression of Integrin alpha4beta7 a4b7 and MAdCAM-1 in ileocolonic mucosal biopsies of treated and untreated patients with Crohns disease and controls | $37,908 | 0 | 2 |
| Vortioxetine as a potential enhancer of cognition in schizophrenia | $36,374 | 0 | 1 |
| Role of a4b7 integrin blockade in the prevention and treatment of Graft Versus Host Disease using a humanized mouse model | $35,615 | 0 | 1 |
| Old Study Number- VOR-IIT-0006 IRISVortioxetine for Menopausal Depression | $34,335 | 0 | 1 |
| Effect of Integrin Blockade on Intramucosal Regulatory to Effector T Cell Ratio | $32,029 | 0 | 1 |
| Role of a4B7 integrin blockade in the prevention and treatment of Graft Versus Host Disease using a humanized mouse model | $23,743 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Gastroenterology | $403,398 | 19 | $21,231 |
| Cardiovascular Disease | $207,700 | 3 | $69,233 |
| Internal Medicine | $152,748 | 11 | $13,886 |
| Hematology & Oncology | $148,261 | 8 | $18,533 |
| Medical Oncology | $125,928 | 3 | $41,976 |
| Endocrinology, Diabetes & Metabolism | $109,359 | 6 | $18,226 |
| Hematology | $57,122 | 3 | $19,041 |
| Specialist | $50,308 | 2 | $25,154 |
| Hypertension Specialist | $17,059 | 1 | $17,059 |
| Dermatology | $12,100 | 1 | $12,100 |
| Nephrology | $5,000 | 1 | $5,000 |
| Gynecologic Oncology | $4,200 | 1 | $4,200 |
| Clinical & Laboratory Immunology | $4,061 | 1 | $4,061 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Robert Chilton, Do, DO | Cardiovascular Disease | San Antonio, TX | $96,735 | $0 |
| Sanjay Rajagopalan, Md, MD | Cardiovascular Disease | Baltimore, MD | $94,077 | $0 |
| Vivian Fonseca, Md, MD | Endocrinology, Diabetes & Metabolism | New Orleans, LA | $72,649 | $0 |
| Jean-Frederic Colombel, M.d, M.D | Gastroenterology | New York, NY | $64,027 | $0 |
| Craig Moskowitz, Md, MD | Medical Oncology | Miami, FL | $63,842 | $0 |
| Ronnie Fass, Md, MD | Gastroenterology | Cleveland, OH | $57,293 | $0 |
| David Peura, M.d, M.D | Gastroenterology | Charlottesville, VA | $53,179 | $0 |
| Dr. Marla Dubinsky, M.d, M.D | Specialist | New York, NY | $44,196 | $0 |
| Shaji Kumar, M.d, M.D | Hematology & Oncology | Rochester, MN | $39,891 | $0 |
| Dana Lukin, M.d., Ph.d, M.D., PH.D | Gastroenterology | New York, NY | $36,933 | $0 |
| Ruben Niesvizky, Md, MD | Hematology & Oncology | New York, NY | $34,809 | $0 |
| Anas Younes, M.d, M.D | Medical Oncology | New York, NY | $33,867 | $0 |
| Prashant Kapoor, Md, MD | Internal Medicine | Rochester, MN | $33,514 | $0 |
| Mohammad Jahanzeb, Md, MD | Hematology & Oncology | Boca Raton, FL | $31,553 | $0 |
| Francis Buadi, Md, MD | Hematology & Oncology | Rochester, MN | $30,709 | $0 |
| Morie Gertz, M.d, M.D | Hematology | Rochester, MN | $29,636 | $0 |
| Dr. Ashwin Ananthakrishnan, M.d., M.p.h, M.D., M.P.H | Internal Medicine | Boston, MA | $28,364 | $0 |
| Steven Horwitz, Md, MD | Medical Oncology | New York, NY | $28,219 | $0 |
| Edward Loftus, M.d, M.D | Gastroenterology | Rochester, MN | $26,648 | $0 |
| Dr. Parambir Dulai, M.b.b.s, M.B.B.S | Gastroenterology | Chicago, IL | $25,026 | $0 |
| Ellen Scherl, Md, MD | Gastroenterology | New York, NY | $24,914 | $0 |
| Tauseef Ali, M.d, M.D | Gastroenterology | Oklahoma City, OK | $23,948 | $0 |
| Dr. Tatyana Feldman, M.d, M.D | Hematology | Hackensack, NJ | $22,386 | $0 |
| Dr. Christian Stone, Md, Mph, MD, MPH | Gastroenterology | Las Vegas, NV | $18,330 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $17,059 | $0 |
About Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. has made $4.4M in payments to 61 healthcare providers, recorded across 400 transactions in the CMS Open Payments database. In 2019, the company paid $1.4M. The top product by payment volume is Entyvio ($2.2M).
Payments were distributed across 13 medical specialties. The top specialty by payment amount is Gastroenterology ($403,398 to 19 doctors).
Payment categories include: Food & Beverage ($5,771), Consulting ($503,642), Research ($3.1M), Travel & Lodging ($270,183).
Takeda Pharmaceuticals International, Inc. is associated with 1 products in the CMS Open Payments database.